SCHEMBL20744189

SCHEMBL20744189

COc1ccc(C2CCN(C(=O)CCC(F)(F)F)CC2)cn1

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.51
ENPP2 Q13822 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30305353 1.00 NAMPT (0.51) NAMPTENPP2
SCHEMBL20743088 0.89 KDM1A (0.47) NAMPT
SCHEMBL20744291 0.84
SCHEMBL30305369 0.84
SCHEMBL20744360 0.83 EPHX2 (0.48)
SCHEMBL30305346 0.83 EPHX2 (0.48)
SCHEMBL15840435 0.82 ALDH1A1 (0.53)
SCHEMBL15840447 0.78 NPC1 (0.49)
SCHEMBL15840441 0.78 NAMPT (0.50) NAMPT
SCHEMBL20744367 0.78 ADAM17 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240307385-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-19 US claimed
CN-111225910-B Novel compounds 葛兰素史密斯克莱知识产权发展有限公司 2023-03-24 CN claimed
EP-3668853-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2021-09-29 EP claimed
US-20200253967-A1 NOVEL COMPOUNDS BioVersys AG (CH) 2020-08-13 US claimed
EP-3668853-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-06-24 EP claimed
CN-111225910-A Novel compounds 葛兰素史密斯克莱知识产权发展有限公司 2020-06-02 CN claimed
WO-2019034701-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-02-21 WO claimed
US-20240307385-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-19 US disclosed
US-11969423-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-04-30 US disclosed
CN-111225910-B Novel compounds 葛兰素史密斯克莱知识产权发展有限公司 2023-03-24 CN disclosed
EP-3668853-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2021-09-29 EP disclosed
EP-3668853-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2021-09-29 EP disclosed
US-20200253967-A1 NOVEL COMPOUNDS BioVersys AG (CH) 2020-08-13 US disclosed
US-20200253967-A1 NOVEL COMPOUNDS BioVersys AG (CH) 2020-08-13 US disclosed
EP-3668853-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-06-24 EP disclosed
CN-111225910-A Novel compounds 葛兰素史密斯克莱知识产权发展有限公司 2020-06-02 CN disclosed
WO-2019034701-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-02-21 WO disclosed
WO-2019034701-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240307385-A1 NOVEL COMPOUNDS FNTB, SDHA, FDPS NAMPT 471/4885ENPP2 159/4885
US-20200253967-A1 NOVEL COMPOUNDS FNTB, SDHA, FDPS NAMPT 471/4885ENPP2 159/4885
US-11969423-B2 Compounds SDHA, SDHB, FDPS NAMPT 347/4885ENPP2 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.